



Introduced Version

---

---

## SENATE RESOLUTION No. \_\_\_\_

\_\_\_\_\_

### DIGEST OF INTRODUCED RESOLUTION

A SENATE RESOLUTION urging the legislative council to assign to the Health Finance Commission the topic of biosimilar biological products.

---

**Miller Patricia**

---

---

\_\_\_\_\_, read first time and referred to Committee on

---

---

20132883

2013

SR 2527/DI 84+



## SENATE RESOLUTION

---

MADAM PRESIDENT:

I offer the following resolution and move its adoption:

1       A SENATE RESOLUTION urging the legislative council to assign  
2       to the Health Finance Commission the topic of biosimilar biological  
3       products.

4       *Whereas, A biosimilar biological product is defined as a biological*  
5       *product that has been licensed as a biosimilar product under federal*  
6       *law and is highly similar to the reference product with no clinically*  
7       *meaningful difference between the biological product and the*  
8       *reference product in terms of safety, purity, and potency of the product*  
9       *and only minor differences in clinically inactive components; and*

10       *Whereas, It behooves the state of Indiana to study how Indiana law*  
11       *may affect prescribing and substituting of biosimilar biological*  
12       *products for other drugs: Therefore,*

13                       *Be it resolved by the Senate*  
14                       *of the General Assembly of the State of Indiana:*

15       SECTION 1. That the legislative council is urged to assign to the  
16       Health Finance Commission the topic of biosimilar biological products.

